Answer
Mirvetuximab soravtansine (Elahere) is not recommended during pregnancy because its genotoxic DM4 component and effects on actively dividing cells can harm the embryo or foetus, and it may cross the placenta.
Sources for this answer
- ELAHERE 5 mg/mL concentrate for solution for infusionAbbVie Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 2Document updated
Sources checked